Bavarian Nordic A/S

PINK:BVNKF USA Biotechnology
Market Cap
$1.62 Billion
Market Cap Rank
#5587 Global
#3276 in USA
Share Price
$20.71
Change (1 day)
-4.12%
52-Week Range
$20.71 - $24.23
All Time High
$58.02
About

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an or… Read more

Bavarian Nordic A/S (BVNKF) - Total Liabilities

Latest total liabilities as of September 2025: $2.00 Billion USD

Based on the latest financial reports, Bavarian Nordic A/S (BVNKF) has total liabilities worth $2.00 Billion USD as of September 2025.

Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Bavarian Nordic A/S - Total Liabilities Trend (2001–2024)

This chart illustrates how Bavarian Nordic A/S's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.

Bavarian Nordic A/S Competitors by Total Liabilities

The table below lists competitors of Bavarian Nordic A/S ranked by their total liabilities.

Liability Composition Analysis (2001–2024)

This chart breaks down Bavarian Nordic A/S's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 3.84 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.15 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.13 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Bavarian Nordic A/S's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Bavarian Nordic A/S (2001–2024)

The table below shows the annual total liabilities of Bavarian Nordic A/S from 2001 to 2024.

Year Total Liabilities Change
2024-12-31 $3.00 Billion -25.32%
2023-12-31 $4.01 Billion -23.43%
2022-12-31 $5.24 Billion +11.17%
2021-12-31 $4.71 Billion +21.99%
2020-12-31 $3.86 Billion -25.41%
2019-12-31 $5.18 Billion +488.61%
2018-12-31 $880.31 Million +36.19%
2017-12-31 $646.37 Million -19.85%
2016-12-31 $806.46 Million +24.69%
2015-12-31 $646.78 Million +1.83%
2014-12-31 $635.17 Million +33.46%
2013-12-31 $475.92 Million -11.79%
2012-12-31 $539.50 Million -29.84%
2011-12-31 $768.99 Million +17.10%
2010-12-31 $656.69 Million +15.84%
2009-12-31 $566.89 Million -16.53%
2008-12-31 $679.13 Million +32.03%
2007-12-31 $514.39 Million +95.57%
2006-12-31 $263.02 Million -11.87%
2005-12-31 $298.46 Million +4.10%
2004-12-31 $286.71 Million +248.93%
2003-12-31 $82.17 Million -32.24%
2002-12-31 $121.26 Million +583.90%
2001-12-31 $17.73 Million --